Browse > Article
http://dx.doi.org/10.5012/bkcs.2009.30.9.2007

Polymorphic Characterization of Pharmaceutical Solids, Donepezil Hydrochloride, by 13C CP/MAS Solid-State Nuclear Magnetic Resonance Spectroscopy  

Park, Tae-Joon (Dept. of Chemistry and Protein Res. Cener for Bio-Industry, Hankuk University of Foreign Studies)
Ko, Dong-Hyun (CJ Cheil Jedang Corp. Pharmarceutical Research Institute)
Kim, Young-Ju (CJ Cheil Jedang Corp. Pharmarceutical Research Institute)
Kim, Yon-Gae (Dept. of Chemistry and Protein Res. Cener for Bio-Industry, Hankuk University of Foreign Studies)
Publication Information
Bulletin of the Korean Chemical Society / v.30, no.9, 2009 , pp. 2007-2010 More about this Journal
Abstract
Donepezil hydrochloride is a reversible acetylcholinesterase inhibitor that is used in the treatment of Alzheimer’s disease to improve the cognitive performance. It shows different crystalline forms including hydrates. Therefore, it is very important to confirm the polymorphic forms in the formulations of pharmaceutical materials because polymorphs of the same drug often exhibit significant differences in solubility, bioavailability, processability and physical/chemical stability. In this paper, four different forms of donepezil hydrochloride were prepared and characterized using X-ray powder diffraction, Fourier transform infrared, and solid-state nuclear magnetic resonance (NMR) spectroscopy. This study showed that solid-state NMR spectroscopy is a powerful technique for obtaining structural information and the polymorphology of pharmaceutical solids.
Keywords
Donepezil; Pharmaceutical solids; Solid-state NMR; CP/MAS; Polymorphism;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
Times Cited By Web Of Science : 1  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Bennett, A. E.; Rienstra, C. M.; Auger, M.; Lakshmi, K. V.; Griffin, R. G. J. Chem. Phys. 1995, 103, 6951   DOI   ScienceOn
2 Haleblian, J.; McCrone, W. J. Pharm. Sci. 1969, 58, 911   DOI
3 Fukuoka, E.; Makita, M.; Yamamura, S. Chem. Pharm. Bull. 1986, 34, 4314   DOI   ScienceOn
4 Law, S. L.; Lo, W. Y.; Lin, F. M.; Chaing, C. H. Int. J. Pharm. 1992, 84, 161   DOI   ScienceOn
5 Fukuoka, E.; Makita, M.; Yamamura, S. Chem. Pharm. Bull. 1989, 37, 1047   DOI
6 Monkhouse, D. C.; Van, C. L. Drug. Dev. Indust. Pharm. 1984, 10, 1175   DOI
7 Bugay, D. E. Pharm. Res. 1993, 10, 317   DOI   ScienceOn
8 Brittain, H. G. J. Pharm. Sci. 1997, 86, 405   DOI   ScienceOn
9 Shintani, E. Y.; Uchida, K. M. Am. J. Health-Syst. Pharm. 1997, 54, 2805
10 Rho, J. P.; Lipson, L. G. Formulary 1997, 32, 677
11 Bryson, H. M.; Benfield, P. Drugs & Aging 1997, 19, 234
12 Elati, C. R.; Vankawala, P. J. Indian J. Chem. 2005, 44B, 1231
13 Vrbinc, M.; Jordan-Kotar, B.; Smrkolj, M.; Vrecer, F. Acta Chim. Slov. 2007, 54, 254
14 Hartmann, S. R.; Hahn, E. L. Phys. Rev. 1962, 128, 2043
15 Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. Reson. 1982, 49, 341
16 Park, T. J.; Kim, J.; Kim, T. K.; Park, H. M.; Choi, S. S.; Kim, Y. Bull. Kor. Chem. Soc. 2008, 29, 2459   DOI   ScienceOn
17 Park, T. J.; Choi, S. S.; Kim, Y. Bull. Kor. Chem. Soc. 2009, 30, 149   DOI   ScienceOn
18 Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharm. Res. 1995, 12, 945   DOI   ScienceOn
19 Saindon, P. J.; Cauchon, N. S.; Sutton, P. A.; Chang, C. J.; Peck, G. E.; Byrn, S. R. Pahrm. Res. 1993, 10, 197   DOI   ScienceOn
20 Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Applied Spectroscopy Reviews 2008, 43, 202   DOI   ScienceOn
21 Kim, Y. A.; Kim, A. R. Bull. Korean Chem. Soc. 2002, 23, 1729   DOI   ScienceOn
22 Katsuhiko, M.; Sachio, T.; Hiroyuki, K.; Yasuyuki, S.; Tetsuo, H.; Etsuo, Y.; Katsuhide, T. Int. J. Pharm. 2006, 318, 146   DOI   ScienceOn
23 Lubach, J. W; Padden, B. E.; Winslow, S. L.; Salsbury, J. S.; Masters, D. B.; Topp, E. M.; Munson, E. J. Anal. Bioanal. Chem. 2004, 378, 1504   DOI   ScienceOn
24 Park, J. S.; Kang, H. W.; Park, S. J.; Kim, C. K. Eur. J. Pharm. Biopharm. 2005, 60, 407   DOI   ScienceOn